Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Inks Proteomics Deal with AstraZeneca

NEW YORK, Aug. 11 (GenomeWeb News) - Caprion Pharmaceutials said today that it has signed a deal to use its proteomics technology to help AstraZeneca identify biomarkers for pain.


Under the arrangement, Montreal-based Caprion said it will use its CellCarta technology to profile, in specific preclinical models, proteomics changes in plasma that result from drug compound administration.


 "We believe that Caprion's proteomics platform is well suited to identify novel biomarkers that could be used to assess the safety and efficacy of AstraZeneca's experimental compounds," Philippe Walker, vice president of discovery at AstraZeneca R&D Montreal, said in a statement.


Specific terms of the arrangement were not disclosed.